"The Hematology Oncology Practice has served the Upstate of South Carolina for nearly 40 years. The practice has grown to 10 board certified physicians and nine nurse practitioners. Our comprehensive Cancer Center provides onsite infusion for the convenience and comfort of our patients. Our multidisciplinary integrated approach to patient care provides the latest in treatment options and clinical research opportunities. This practice provides patient centered compassionate care. Our goal is to empower patients and families; this partnership leads to superior outcomes. Our practice is a member of Medical Group of the Carolinas (MGC), a large multi-specialty physician group serving Upstate South Carolina and parts of North Carolina."

During the past decade, MGC Hematology Oncology-Union conducted 82 clinical trials. In the 10-year time frame, 82 clinical trials started and 21 clinical trials were completed, i.e. on average, 25.6% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 19 clinical trials were completed. i.e. 61.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MGC Hematology Oncology-Union" #1 sponsor was "National Cancer Institute (NCI)" with 39 trials, followed by "SWOG Cancer Research Network" with 19 trials sponsored, "Alliance for Clinical Trials in Oncology" with 11 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 8 trials sponsored and "Wake Forest University Health Sciences" with 8 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MGC Hematology Oncology-Union" #1 collaborator was "National Cancer Institute (NCI)" with 49 trials as a collaborator, "NRG Oncology" with 10 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "MGC Hematology Oncology-Union" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Invasive Breast Carcinoma" (6 trials), "Recurrent Ovarian Carcinoma" (5 trials) and "Stage IIIA Breast Cancer" (5 trials). Many other conditions were trialed in "MGC Hematology Oncology-Union" in a lesser frequency.

Most popular intervention types in "MGC Hematology Oncology-Union" are "Other" (65 trials), "Drug" (62 trials), "Biological" (38 trials), "Procedure" (25 trials) and "Radiation" (15 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (30 trials), "Questionnaire Administration" (25 trials), "Laboratory Biomarker Analysis" (24 trials), "Biospecimen Collection" (15 trials) and "Computed Tomography" (15 trials). Other intervention names were less common.

The vast majority of trials in "MGC Hematology Oncology-Union" are 76 trials for "All" genders, 16 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "MGC Hematology Oncology-Union". undefined are not yet recruiting, 28 are recruiting, 44 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in MGC Hematology Oncology-Union, 3 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MGC Hematology Oncology-Union, 1 "Phase 1" clinical trials were conducted, 36 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".